A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab

Respiratory Medicine Case Reports

Motohiro Izumi¹  Akira Sugimoto²  Kosuke Sawatari²  Yosuke Eguchi²  Risa Sone²  Tsuyoshi Hattori²  Takashi Mamoto² 

[1] Corresponding author. 500-3, Higashiyama, Naka-ku, Sakai-city, Osaka, Japan.;Bell Land General Hospital, Department of Respiratory Medicine, 500-3, Higashiyama, Naka-ku, Sakai-city, Osaka, Japan;

关键词: Pulmonary sarcomatoid carcinoma;    PD-L1;    Immune checkpoint inhibitor;    Bevacizumab;    Atezolizumab;    Lung cancer;   

DOI  :  

来源: DOAJ

【 摘 要 】

Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT). Positron emission tomography-CT revealed abnormal tracer uptake in the area corresponding to the mass in the upper lobe. Hence, convex-probe endobronchial ultrasound-guided transbronchial needle aspiration was performed. Histological examination revealed dense proliferation of spindle tumor cells and no programmed death-ligand 1 (PD-L1) expression. Thus, he was diagnosed with PSC (cT4N0M1a, clinical stage IVA), and four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab was initiated. Marked shrinkage of the mass and symptomatic improvements were observed following the treatment initiation. Tumor shrinkage was further noted after shifting to maintenance therapy with atezolizumab and bevacizumab; the patient exhibited no symptom exacerbation 2 years later and continued the treatment. Our case showed that four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab could be an effective treatment option for advanced PSC with or without PD-L1 expression.

【 授权许可】

Unknown